Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy
Author:
- 28 February 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (3) , 255-268
Abstract
Introduction: The purpose of this review is to evaluate the cost-effectiveness of allergy immunotherapy (AIT) in the treatment of allergic rhinitis, asthma, and other allergic conditions. Area covered: An extensive search of the PubMed and Medline database (January 1996 up to June of 2020) was conducted using the search terms allergy immunotherapy, pharmacoeconomics, cost-effectiveness, allergic rhinitis, and asthma. Studies were included if they included information on the economics of AIT in comparison to pharmacotherapy in the treatment of allergic rhinitis or asthma either as actual costs or based on theoretical models. Systematic reviews were included if they included information about the cost-effectiveness of AIT. Most clinical trials found significant cost-savings with AIT. The cost-effective time-point ranged from a few months to several years after treatment initiation.. Cost savings were demonstrated as early as 3 months after treatment initiation and were as great as 80% less than SDT in some studies. Expert opinion: There is strong evidence in the collective literature that AIT is cost-effective as compared to SDT alone. The magnitude of AIT’s cost-effectiveness is likely underestimated because most of the studies considered during treatment costs and not AIT’s long-term benefits or preventive/prophylactic effects or its impact on co-morbid conditions.Keywords
This publication has 75 references indexed in Scilit:
- Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in AdultsClinical Drug Investigation, 2013
- The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesisAllergologia et Immunopathologia, 2013
- Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthmaClinical and Translational Allergy, 2013
- Environmental assessment and exposure control: a practice parameter—furry animalsAnnals of Allergy, Asthma & Immunology, 2012
- EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapyClinical and Translational Allergy, 2012
- Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort studyAnnals of Allergy, Asthma & Immunology, 2010
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Pediatric allergic rhinitis: Physical and mental complicationsAllergy and Asthma Proceedings, 2008
- Influence of time horizon and treatment patterns on cost-effectiveness measures: the case of allergen-specific immunotherapy with GrazaxJournal of Medical Economics, 2007
- Economic impact and quality-of-life burden of allergic rhinitisCurrent Medical Research and Opinion, 2004